Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma Virus (RSV) and Cancer

Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...

The Retinoblastoma Gene

The Retinoblastoma Gene

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
The first-ever tumor suppressor gene called Rb was identified in retinoblastoma - a rare eye tumor in children. In inherited forms of the disease, a child inherits one defective copy of the Rb gene, which predisposes them to retinoblastoma. However,...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Paediatric therapeutic development workshop on medulloblastoma.

British journal of cancer·2026

Same author

Loss of BAX in a neuroblastoma patient reveals delayed apoptosis but sustained chemotherapy sensitivity.

NPJ precision oncology·2026

Same author

Fatigue after pediatric bone sarcoma: prevalence and associated factors in pediatric and adult patients and survivors after treatment.

Journal of cancer survivorship : research and practice·2026

Same author

Paediatric Therapeutic Development Workshop on rhabdomyosarcoma.

British journal of cancer·2026

Same author

Critical appraisal of patient-reported and clinician-reported outcome measures assessing functional outcomes in lower extremity bone sarcoma patients-a COSMIN-based systematic review.

Journal of patient-reported outcomes·2026

Same author

Who leads, who treats, what dose? European paediatric differentiated thyroid carcinoma practice-an European Cooperative Study Group for Paediatric Rare Tumours survey.

European journal of endocrinology·2026

Search research articles

Related Experiment Video

Updated: Jan 15, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Childhood, Adolescent and Young Adult Poor-Prognosis Rhabdomyosarcoma.

Ajla T Wasti^1,2,3, Gianni Bisogno^4,5, Raquel Hladun⁶

¹Children and Young People's Unit, The Royal Marsden NHS Foundation Trust, Sutton SM2 5PT, UK.

|October 16, 2025

Summary

Rhabdomyosarcoma (RMS) is a common childhood cancer. Survival is limited for high-risk patients, including those with specific genetic variants or metastatic disease, necessitating novel therapeutic approaches.

Keywords:

adolescent chemotherapy child metastatic novel approaches radiotherapy relapse rhabdomyosarcoma surgery young adult

More Related Videos

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Related Experiment Videos

Last Updated: Jan 15, 2026

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Tumorsphere Derivation and Treatment from Primary Tumor Cells Isolated from Mouse Rhabdomyosarcomas

Published on: September 13, 2019

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

A Syngeneic Orthotopic Osteosarcoma Sprague Dawley Rat Model with Amputation to Control Metastasis Rate

Published on: May 3, 2021

Area of Science:

Pediatric Oncology
Cancer Genomics
Sarcoma Research

Background:

Rhabdomyosarcoma (RMS) is the most frequent soft tissue sarcoma in pediatric and young adult populations.
Current survival improvements primarily benefit patients with localized disease and favorable biologic features.
Existing prognostic factors include genetic fusions (e.g., PAX3::FOXO1), disease extent, tumor site, size, and patient age.

Purpose of the Study:

To review the clinical characteristics and treatment strategies for the poorest prognostic groups of pediatric-type RMS.
To focus on very high-risk or relapsed/progressive disease categories.
To summarize emerging diagnostic and therapeutic innovations for these challenging cases.

Main Methods:

Review of clinical characteristics of high-risk RMS patients.
Analysis of standard multimodality treatments within international clinical trials.
Summary of novel diagnostic and therapeutic approaches.

Main Results:

High-risk RMS includes patients with PAX3::FOXO1 fusion, locoregional nodal involvement, other poor-risk genetic variants (MYOD1, TP53), adolescent/young adult patients, metastatic disease, and relapsed/refractory cases.
Treatment stratification relies on established clinicopathologic and evolving molecular factors.
Standard treatments are guided by sequential international clinical trials.

Conclusions:

Patients with specific genetic profiles and advanced disease stages represent the poorest prognostic groups in RMS.
Evolving risk stratification, informed by molecular biology, is crucial for guiding treatment intensity.
Novel diagnostic and therapeutic strategies are essential to improve outcomes for high-risk and relapsed RMS patients.